Research recommendations coming out of this guidance Further evidence to address uncertainties about the relative clinical and cost effectiveness of UroLift compared with Rezum, especially in the NHS, would be welcome. This should include: • exploring long-term clinical outcomes and reintervention rates after UroLift • assessing the suitability of UroLift for prostates larger than 80 ml and for those with an obstructive median lobe.
Further evidence to address uncertainties about the relative clinical and cost effectiveness of UroLift compared with Rezum, especially in the NHS, would be welcome. This should include: • exploring long-term clinical outcomes and reintervention rates after UroLift • assessing the suitability of UroLift for prostates larger than 80 ml and for those with an obstructive median lobe.